ERBB2 and breast cancer: Here, we performed a comprehensive analysis of the clinical, genomic, and transcriptomic data of HR+/HER2– breast cancers (n = 351) in the Chinese Breast Cancer Genome Atlas (CBCGA) cohort, which we previously reported (11) and revealed that there were 2 immunologically heterogeneous phenotypes.